EZH2 and Miyoshi myopathy: Our present findings show that EZH2 inhibition leads to upregulation of a set of tumor suppressor microRNAs targeting important MM-associated oncogenes, and suggest EZH2 inhibitors and the silenced tumor suppressor microRNAs as possible novel therapeutic strategies in MM.